Thank you, operator, and welcome, everyone, to the Bactiguard presentation of the first quarter of 2026. Patrick and I will go through the presentation together today. I'll start with an overview of the quarter and our strategic progress. And Patrick will then walk you through our financials in more detail. We will, of course, open up for questions at the end.
The title of today's presentation is Building Momentum Through Partnerships, Regulatory Progress, and Organizational Strength. And that reflects how we view this quarter, not driven by a single event, but by continued execution across several areas that are important for Bactiguard's long-term development. I'm actually joining you today from the US, where the Heart Rhythm Society meeting starts in Chicago later today. And with that, let me start with a high-level overview of the quarter.
Next slide please.
Starting with the key figures and highlights from a financial perspective, we delivered continued profitability with adjusted EBITDA of 4.9 million SEK, and reported revenues were lower compared with the same quarter last year, and we will come back to the underlying drivers behind that as we move through the presentation. Strategically, however, the quarter has been an important one. We saw increased sales of Bactiguard coated products across our collaborations, and BD has initiated sales of the Bactiguard coated Foley in parts of Europe, marking another step in expanding the reach of our technology. This was also the first reported quarter under the updated business setup with Zimmer Biomet that we announced in late December, and which has been an important transition point for that partnership.
During the quarter, we also continued to invest in regulatory-related activities, which are critical for supporting both existing partners and future collaborations, and we delivered a solid performance in our Wound Management portfolio, with Hydrocyn aqua continuing to be the main driver overall. This reflects the steady execution of our strategy, even in a quarter where reported numbers continue to be impacted by external factors such as currency.
Next slide please. Our focus remains on a defined set of strategic therapeutic areas: orthopedics, vascular access, cardiology, neurology, and urology. These are areas where the unmet medical need is clear and where our technology has the potential to deliver both clinical and commercial value. During the quarter, we maintained a high level of engagement across all of these areas. These include early stage discussions with potential partners, work in application development areas, and technical evaluations, again with potential partners.
An important part of this engagement has been our presence at multiple international congresses, where we meet with potential partners and with clinicians in the field. These interactions have been critical for building relationships, understanding our potential partners' needs, and validating where our infection prevention technology can create the most value, thus allowing us to initiate meaningful discussions with potential relevant partners. And this is one of the reasons why I am in Chicago, as it takes typically several years from development to commercialization. We should not expect all of these early-stage activities to translate into significant short-term revenues, but they are essential for building a pipeline that supports our long-term growth in our licensed business.
Next slide, please. Turning now to our partnership with BD. This is a long-standing relationship that continues to evolve and expand the reach of BD Bactiguard coated Foley catheters into new markets during the quarter. Sales of the Bactiguard coated urinary catheters began in parts of Europe, and preparations are ongoing for further expansion into additional markets. A key element of this expansion is our close operational collaboration with our partner BD during the quarter.
Bactiguard teams have been involved in training and support activities together with BD, particularly for new markets. This includes project education, technical training and support for both distributors and BD sales organizations to ensure that the clinical value of the coated Foley catheters is clearly understood. These activities are an important part of how we work with partners across the entire value chain, not only licensing our technology, but also actively supporting successful market introductions. While revenues from the BD partnership were lower in the quarter compared with last year, the underlying momentum remains positive, and we continue to see in-market unit sales growth of Bactiguard coated Foleys. The partnership is strategically important for both of us, and we continue to see long-term potential as additional markets come online.
Moving on to Zimmer Biomet, as mentioned earlier, this quarter represents the first reported period under the updated business setup for the ZNN Bactiguard Trauma Nail system. The focus during the quarter has been on two main activities: first, advancing the MDR transition in Europe, which is a necessary step to ensure continued and expanded commercialization under the current regulatory framework; and secondly, continuing post-market clinical studies. These studies are also critical for strengthening the clinical evidence base and supporting future commercial developments. While this exciting phase in the Zimmer Biomet Partnership is about building the foundation more than delivering immediate volume growth, it is an important step towards increasing transparency and predictability in our revenues over time. Beyond the operational progress, I want to emphasize that the collaboration with Zimmer Biomet remains constructive and forward-looking, with a shared commitment to strengthening the clinical and regulatory position of Bactiguard coated trauma implants as a meaningful pillar in the Zimmer Biomet infection prevention category.
Next slide please. Turning to Wound Management, the portfolio delivered a solid performance in the quarter, with Hydrocyn aqua continuing to be the main contributor. While suture sales are now stabilizing. Revenues were lower compared with the strong first quarter last year due to timing effects of certain tenders in certain markets, but the underlying development does remain positive. During the quarter, we continued onboarding distributors entering new markets and received encouraging feedback related to both demand and clinical relevance of our products across both our existing and our new markets. We also continued activities related to MDR for this portfolio as well, and ensuring that the portfolio is well positioned to support future growth, as Wound Management remains an important, complementary part of the Bactiguard portfolio, providing diversification and opportunities to apply our infection prevention expertise in additional areas.
And with that, I will hand back to Patrick, who will take you through the financials in more detail.